- Home
- SFWL vs TNYA Comparison
SFWL vs TNYA Comparison
Compare SFWL & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- TNYA
- Stock Information
- Founded
- SFWL 2001
- TNYA 2016
- Country
- SFWL China
- TNYA United States
- Employees
- SFWL N/A
- TNYA N/A
- Industry
- SFWL Trucking Freight/Courier Services
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- SFWL Industrials
- TNYA Health Care
- Exchange
- SFWL Nasdaq
- TNYA Nasdaq
- Market Cap
- SFWL 74.2M
- TNYA 74.5M
- IPO Year
- SFWL 2023
- TNYA 2021
- Fundamental
- Price
- SFWL $1.02
- TNYA $0.46
- Analyst Decision
- SFWL
- TNYA Strong Buy
- Analyst Count
- SFWL 0
- TNYA 6
- Target Price
- SFWL N/A
- TNYA $8.60
- AVG Volume (30 Days)
- SFWL 10.3K
- TNYA 2.3M
- Earning Date
- SFWL 06-10-2025
- TNYA 05-07-2025
- Dividend Yield
- SFWL N/A
- TNYA N/A
- EPS Growth
- SFWL 4.79
- TNYA N/A
- EPS
- SFWL 0.13
- TNYA N/A
- Revenue
- SFWL $504,158,000.00
- TNYA N/A
- Revenue This Year
- SFWL N/A
- TNYA N/A
- Revenue Next Year
- SFWL N/A
- TNYA N/A
- P/E Ratio
- SFWL $7.72
- TNYA N/A
- Revenue Growth
- SFWL 24.75
- TNYA N/A
- 52 Week Low
- SFWL $0.81
- TNYA $0.36
- 52 Week High
- SFWL $2.15
- TNYA $4.29
- Technical
- Relative Strength Index (RSI)
- SFWL 54.75
- TNYA 48.93
- Support Level
- SFWL $0.94
- TNYA $0.43
- Resistance Level
- SFWL $1.02
- TNYA $0.46
- Average True Range (ATR)
- SFWL 0.05
- TNYA 0.04
- MACD
- SFWL -0.00
- TNYA 0.01
- Stochastic Oscillator
- SFWL 68.67
- TNYA 71.43
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.